Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer

Abstract : Triple-negative breast cancer (TNBC) is characterized by overexpression of epidermal growth factor receptor (EGFR) and activation of its downstream signaling pathways. Dual targeting of EGFR using one monoclonal antibody (mAb; cetuximab or panitumumab) and one tyrosine kinase inhibitor (EGFR-TKI; gefitinib or erlotinib) is a potential therapeutic approach. We investigated the effect of these therapies in EGFR-expressing TNBC cell lines that do or do not harbor the main activating mutations of EGFR pathways. Cell lines were sensitive to EGFR-TKIs, whereas mAbs were active only in MDA-MB-468 (EGFR amplification) and SUM-1315 (KRAS and PTEN wild-type) cells. MDA-MB-231 (KRAS mutated) and HCC-1937 (PTEN deletion) cells were resistant to mAbs. The combined treatment resulted in a synergistic effect on cell proliferation and superior inhibition of the RAS/MAPK signaling pathway in mAb-sensitive cells. The anti-proliferative effect was associated with G1 cell cycle arrest followed by apoptosis. Sensitivity to therapies was characterized by induction of positive regulators and inactivation of negative regulators of cell cycle. These results suggest that dual EGFR inhibition might result in an enhanced antitumor effect in a subgroup of TNBC. The status of EGFR, KRAS and PTEN could be used as a molecular marker for predicting the response to this therapeutic strategy.
Complete list of metadatas

Cited literature [77 references]  Display  Hide  Download

https://hal-clermont-univ.archives-ouvertes.fr/hal-01671418
Contributor : Corinne Aubel <>
Submitted on : Friday, December 22, 2017 - 11:29:02 AM
Last modification on : Friday, April 26, 2019 - 3:55:11 PM

File

12037-181237-1-PB.pdf
Publication funded by an institution

Identifiers

Collections

Citation

Abderrahim Guerrab, Mahchid Bamdad, Fabrice Kwiatkowski, Yves-Jean Bignon, Frédérique Penault-Llorca, et al.. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. Oncotarget, Impact journals, 2016, ⟨10.18632/oncotarget.12037⟩. ⟨hal-01671418⟩

Share

Metrics

Record views

209

Files downloads

174